Menu Search
Equities

Dynavax Technologies Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DYF1:FRA

Dynavax Technologies Corp

Actions
  • Price (EUR)12.64
  • Today's Change0.00 / 0.00%
  • Shares traded184.00
  • 1 Year change+2.47%
  • Beta0.9238
Data delayed at least 15 minutes, as of Jan 30 2026 07:21 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

  • Revenue in USD (TTM)330.51m
  • Net income in USD-43.40m
  • Incorporated2000
  • Employees405.00
  • Location
    Dynavax Technologies Corp2100 Powell Street, Suite 720EMERYVILLE 94608United StatesUSA
  • Phone+1 (510) 848-5100
  • Fax+1 (510) 848-1327
  • Websitehttps://www.dynavax.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.